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Abstract
Reactive oxygen species (ROS) produced by brain-infiltrating macrophages and neutrophils, as well as resident microglia,
are pivotal to pathogen clearance during viral brain infection. However, unchecked free radical generation is also
responsible for damage to and cytotoxicity of critical host tissue bystander to primary infection. These unwanted effects of
excessive ROS are combated by local cellular production of antioxidant enzymes, including heme oxygenase-1 (HO-1) and
glutathione peroxidase 1 (Gpx1). In this study, we showed that experimental murine herpes encephalitis triggered robust
ROS production, as well as an opposing upregulation of the antioxidants HO-1 and Gpx1. This antioxidant response was
insufficient to prevent tissue damage, neurotoxicity, and mortality associated with viral brain infection. Previous studies
corroborate our data supporting astrocytes as the major antioxidant producer in brain cell cultures exposed to HSV-1
stimulated microglia. We hypothesized that stimulating opposing antioxidative responses in astrocytes, as well as neurons,
would mitigate the effects of ROS-mediated neurotoxicity both in vitro and during viral brain infection in vivo. Here, we
demonstrate that the addition of sulforaphane, a potent stimulator of antioxidant responses, enhanced HO-1 and Gpx1
expression in astrocytes through the activation of nuclear factor-E2-related factor 2 (Nrf2). Additionally, sulforaphane
treatment was found to be effective in reducing neurotoxicity associated with HSV-stimulated microglial ROS production.
Finally, intraperitoneal injections of sulforaphane into mice during active HSV infection reduced neuroinflammation via a
decrease in brain-infiltrating leukocytes, macrophage- and neutrophil-produced ROS, and MHCII-positive, activated
microglia. These data support a key role for astrocyte-produced antioxidants in modulating oxidative stress and neuronal
damage in response to viral infection.
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Introduction
The first line in defense of the brain against invading viral
pathogens is the activation of local microglia and the recruitment
of peripheral leukocytes, including macrophages and neutrophils.
These cells work to eliminate the invading pathogen through the
rapid and robust production of reactive oxygen species (ROS).
Some of the reactive species generated include superoxide (O
22),
hydroxyl radical (OH), hydrogen peroxide (H2O2), hypochlorite
(OCl
2), and peroxynitrite (OONO
2). ROS production, while
beneficial in clearing invading pathogens, can also cause
irreparable harm through oxidative damage to crucial host cells.
ROS have been implicated in toxicity associated with diverse
neurodegenerative diseases such as Alzheimer’s disease, Parkin-
son’s disease, and Amyotrophic lateral sclerosis [1,2]. Similarly,
ROS production and its associated oxidative tissue damage
contribute to herpes simplex virus (HSV)-1-induced neuropathol-
ogy [3,4,5].
The brain employs various defense mechanisms to combat free-
radical mediated oxidative tissue damage and subsequent
neurotoxicity, including the upregulation of phase II antioxidant
enzymes. Antioxidants are important because they directly remove
reactive species from the extracellular matrix limiting free radical
exposure to healthy tissues. Cellular oxidative stress triggers
antioxidant production through nuclear translocation of the
oxidative stress-induced transcription factor, nuclear factor-E2-
related factor 2 (Nrf2). Nrf2 binds to an antioxidant response
element (ARE) to induce transcription of multiple antioxidant
genes, including heme oxygenase-1 (HO-1) and glutathione
peroxidase-1 (Gpx1) [6]. Increased antioxidant enzyme expression
has been shown to decrease neurotoxicity in models of ischemia
and HIV-associated neurocognitive disorders [7,8,9]. Thus,
modulation of antioxidant responses is a promising strategy for
preventing secondary tissue damage from free-radicals during viral
brain infection.
Sulforaphane (1-isothiocyanato-4-methylsulfinylbutane; SFN),
an isothiocyanate that is naturally found in cruciferous vegetables,
is a potent inducer of cellular antioxidants. SFN acts through the
Nrf2/ARE pathway to enhance production of antioxidant
tripeptides (glutathione; GSH) via the upregulation of the modifier
and catalytic subunits of glutamate cysteine ligase GCLM and
GCLC, respectively.[10], as well as by inducing transcription of
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In vitro studies indicate that SFN can reduce ROS production in
BV2 cells, a microglial-like cell line, as well as down-regulate
macrophage activation [12]. In addition, SFN is an excellent
candidate to modulate the antioxidant response during brain
inflammation because of its ability to permeate the blood-brain
barrier [12]. Indeed, peripheral injection of SFN into mice has
been shown to confer anti-inflammatory and neuroprotective
action in models of neurodegenerative diseases [13] and pathogen-
induced brain inflammation [12].
HSV-1 infection of the brain results in devastating necrotizing
encephalitis. Using a murine model of herpes encephalitis we have
shown that intranasal delivery of HSV triggers a robust immune
response, which includes the activation of resident microglial cells,
infiltration of leukocytes, production of proinflammatory media-
tors, and focal tissue damage which, if left untreated, can result in
prolonged neuroinflammation and compromised brain function or
death [5,14,15,16,17]. It is becoming increasingly clear that ROS
contribute to the secondary tissue damage that occurs during and
subsequent to viral brain infection [18,19]. Biproducts of oxidative
tissue damage, including 8-isoprostane and 8-hydroxydeoxygua-
nosine, have been detected both during active herpes encephalitis
as well as during latent herpes infection [5,19]. These studies
indicate that the neurotoxic effects observed during herpes
encephalitis may not be simply due to viral replication, but may
also result from secondary tissue damage originating from host-
generated ROS.
In this study, we hypothesized that ROS-mediated neurotox-
icity associated with experimental herpes encephalitis can be
modulated by stimulating opposing antioxidative responses. In vivo
analysis of ROS in infected mice confirmed the presence of
significant oxidative stress during the peak of viral infection.
Despite a concomitant increase in antioxidant enzyme mRNA
expression in vivo, infected mice still amass significant oxidative
tissue damage. Treatment of both neural cultures and purified
astrocytes with SFN in vitro resulted in the robust expression of
antioxidants which, subsequently, conferred protection to neurons
upon exposure to HSV-stimulated, ROS-producing microglia.
Furthermore, we show that systemic administration of SFN
reduced macrophage and neutrophil brain infiltration, ROS
production, and microglial cell activation in vivo during viral
encephalitis.
Results
Robust ROS production and antioxidant gene induction
during herpes encephalitis
We have previously shown that herpes encephalitic mice exhibit
increased accumulation of oxidative tissue damage biproducts [5].
Direct monitoring of in vivo ROS to establish the presence of
elevated free radicals in the brains of HSV-1 infected mice has not
been performed, but is essential to confirm the role of oxidative
stress on herpes encephalitis-associated pathology. Using conju-
gated antibodies for CD11b and CD45, we have established a flow
cytometry antibody staining regiment for the separation of brain
infiltrating leukocytes (macrophages/neutrophils (CD11b
+,
CD45
hi) and brain-resident microglia (CD11b
+, CD45
int) [5].
This, in combination with 29,79-Dichlorofluorescein diacetate
(DCFH-DA), a fluorescent indicator of intracellular ROS, enabled
quantification of free radical production by brain infiltrating
monocytes during viral infection. Confirming our previous studies,
we found that HSV-1 infection resulted in the robust migration of
CD45+,CD11b
hi macrophages/neutrophils into the brain at 7 d
post-infection (p.i.). At this time point post-infection, the majority
of CD11b
+, CD45
hi cells are macrophages, with ,10% being
neutrophils [5]. Analysis of CD45+,CD11b
hi macrophages/
neutrophils for DCFH-DA fluorescence revealed a significant
increase in ROS production in the brains of HSV-1 infected mice
at 7 d p.i. compared to saline-infected controls (Figure 1).
We next investigated whether increased ROS levels in the brain
of herpes encephalitic mice were associated with concomitant
upregulation of a combatant and opposing antioxidative stress
response. Using semi-quantitative, real-time (RT)-PCR, we
probed Nrf2 as well HO-1 and Gpx1, two prototypical Nrf2-
transcribed antioxidant proteins that exhibit neuroprotective
capabilities during brain inflammation [13,20], for changes in
mRNA expression. In the subcortex of HSV-1 infected mice, we
detected significantly elevated gene expression of both HO-1
(*p=0.01) and Gpx1 (*p=0.001) at 7 d p.i., while Nrf2 gene
expression was not elevated compared to control mice (Figure 2).
Astrocytes mediate antioxidative stress responses
induced by HSV-1 stimulated murine microglia
Exposure of cultured microglia to HSV-1 results in their
activation, including production of neuroinflammatory cytokines,
Figure 1. Increased brain ROS levels during herpes encephalitis. Balb/c mice were infected intranasally with 2610
5 PFU of HSV-1 strain 17
syn+ (n=10). An equal volume of saline was delivered to control mice (n=8). At 7 d p.i. whole brains were pooled, mononuclear cells were isolated
and analyzed via flow cytometry using fluorescent-conjugated antibodies, CD11b-APC and CD45-APC-Cy7. CD11b
+, CD45
hi macrophages/neutrophils
were gated for further analysis of intracellular ROS via detection of DCFH-DA (20 mM). A) DCFH-DA fluorescence spectrum in CD11b
+, CD45
hi cells
from saline (blue) and HSV-infected (red) mice. Non-DCFH-loaded control is black. Composite (B) and individual (C) ROS data are presented as fold
induction of HSV-infected mice (n=5) over controls (n=5). *p,0.05.
doi:10.1371/journal.pone.0036216.g001
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microglial intracellular ROS production and, when co-cultured
with mixed neural cultures (MNCs), consisting of approximately
85–90% neurons, 10–15% astrocytes and ,2% microglia, results
in the accumulation of significant oxidative damage and
neurotoxicity after 48 h. Using this co-culture model in conjunc-
tion with semi-quantitative RT-PCR, we investigated the ability of
HSV-stimulated microglial ROS to induce an antioxidant
response in both MNC and purified murine astrocytes. We found
that the addition of HSV-stimulated microglia (1:5 microglia:
neural cell ratio) did not result in a significant upregulation of Nrf2
or Gpx1 by 48 h post-incubation (Figure 3A). A small but
significant transient upregulation of HO-1 mRNA was observed at
24 h post-incubation in MNC treated with either unstimulated
(p#0.05) or HSV-stimulated microglia (p#0.001). This correlated
with higher HO-1 expression in cultures with HSV-stimulated
microglia than those receiving unstimulated microglia (p#0.05).
Astrocyte-specific upregulation of antioxidants has been iden-
tified as a preferential pathway for protection in the face of disease-
associated neurotoxicity [21,22]. Because astrocytes make up only
a fraction of the cells in our MNCs, we prepared cultures of
purified murine astrocytes to investigate the ability of HSV-
stimulated microglial to initiate an astrocyte-specific antioxidant
response. Using these cultures, we found that, in contrast to
MNCs, purified mouse astrocytes exposed to virus-activated
microglia (1:5 microglia to astrocyte ratio) showed a significant
induction of HO-1 (p#0.0001; ANOVA single factor with PLSD
Post-hoc analysis) and Gpx1 (p#0.0001) mRNA by 48 h post-
incubation (Figure 3B). At 48 h post-incubation, Nrf2 mRNA
expression was elevated compared to astrocyte only and
unstimulated microglia controls, but did not reach statistical
significance.
A battery of antioxidant enzymes are activated in response to
oxidative stress including glutamate cysteine ligase (GCL), the rate
limiting enzyme of glutatione biosynthesis [23]. GCL is composed
of a catalytic (GCLC) and modifier (GCLM) subunit, of which the
expression of GCLM is regulated by Nrf2. Recent studies report
astrocyte generated GSH is important for neuronal protection
during excitotoxicity and some neurodegenerative diseases
[21,22]. Therefore, we investigated the effect of HSV-infected
microglia on GSH production in MNCs. We found a reduction of
total GSH concentration in MNC 48 h following the addition of
HSV-stimulated microglia (p#0.0001; ANOVA single factor with
a PLSD Post-hoc analysis)(Figure 4). HSV-stimulated microglia
did not affect GCLM mRNA expression in MNC or astrocytes.
Sulforaphane protects MNC from HSV-stimulated
microglial toxicity
In the following studies, we investigated the efficacy of SFN, a
potent stimulator of antioxidants, in protecting MNCs against the
neurotoxic effects of virally-stimulated microglial cell-produced
ROS. We verified the ability of SFN to induce a robust anti-
oxidative stress response in MNCs by RT-PCR and Western blot.
Expression analysis of MNC mRNA showed a dose-dependent
increase in gene transcription of two Nrf2-regulated antioxidant
proteins, HO-1 (Figure 5A) and GCLM (Figure 5B) following an 8
and 24 h SFN exposure. HO-1 protein expression was dose-
dependently elevated at 8 and 24 h post-SFN treatment
(Figure 5C). These data were confirmed via immunocytochemistry
which detected elevated levels of HO-1 in SFN (3 mM) treated
MNCs compared to untreated controls (Figure 5E). Similarly, 24 h
SFN treatment resulted in a dose-dependent increase in MNC
GSH (0.1 mM SFN, p=0.0295; 0.3 mM SFN, p=0.0029)
biosynthesis confirming the functional output of SFN-induced
expression of GCLM (Figure 5D). Interestingly, we found that the
SFN antioxidant response was primarily in astrocytes as shown via
colocalization of HO-1 positive cells in MNCs with glial fibrillary
acidic protein (GFAP), an astrocyte-specific marker (Figure 5E).
SFN is known to act through the Nrf2/ARE pathway to initiate
the robust production of phase II antioxidants. To confirm our
finding that SFN increases HO-1 expression in mouse astrocytes,
we verified that SFN treatment initiated antioxidant production
through the activation of the Nrf2/ARE pathway. To this end, we
transduced purified mouse astrocytes with an ARE-Luciferase
lentivirus reporter system, where the lentivirus reporter is active in
transduced cells only upon the binding of Nrf2 to the ARE
upstream of luciferase. Using this assay, we found that 3 mM SFN
resulted in the activation of Nrf2/ARE-dependent transcription at
4 h (p=0.007) and 8 h (p=0.006) post-treatment when compared
to untreated ARE-Luciferase expressing astrocytes (Figure 5F).
To investigate the protective capability of SFN on microglial
cell-induced neurotoxicity we pretreated MNC derived from b-
actin promoter-luciferase transgenic Balb/c mice with SFN for
24 h prior to adding HSV-stimulated microglial cells at a 1:5
microglia to neuron ratio. Because b-actin promoter-luciferase
transgenic mice ubiquitously express the luciferase enzyme, in
these studies, reduced luciferin intensity was indicative of an
increase in neural toxicity. Similar to our previously published
data [3], addition of HSV-stimulated microglial cells onto MNC
resulted in a 40% reduction in luciferase activity indicating
significant neurotoxicity. SFN pretreatment (3.0 mM) completely
attenuated virus-stimulated microglial toxicity while lower con-
centrations (0.1, 0.3, 1.0 mM) of SFN resulted in a dose-dependent
decrease in toxicity (Figure 5A). Immunohistochemical staining for
MAP-2, which is specifically localized to neuronal dendrites,
confirmed neuronal damage was blunted by SFN (Figure 5B).
Neurotoxicity associated with virus-stimulated microglia appears
to primarily affect the integrity of dendritic processes since HSV-
stimulated microglia only mildly (,15%) decreased neuronal
survival. Moreover, SFN pretreatment did not dramatically
increase neuronal survival in cultures with HSV-stimulated
microglia. Neuronal survival was determined by assessing the
number of cells double-labeled with NeuN, an neuron-specific
antibody, and the nuclear intercolating dye, Hoechst 33342.
Figure 2. Antioxidant gene expression is upregulated in the
brains of mice with herpes encephalitis. Balb/c mice were infected
intranasally with 2610
5 PFU of HSV-1 strain 17 syn+ (n=7). An equal
volume of saline was delivered to control mice (n=6). At 7 d p.i. mice
were anaesthetized, dissected and 2 mm-thick sections of subcortical
brain tissue were collected for mRNA extraction, cDNA synthesis and
semi-quantitiative PCR analysis of HO-1 (*p=0.01), Gpx1 (*p=0.001),
and Nrf2 expression.
doi:10.1371/journal.pone.0036216.g002
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inflammation and ROS production in vivo
We next tested the effect of intraperitoneal (i.p.) SFN injection
on brain inflammation and ROS production associated with
herpes encephalitis. To minimize the effect of SFN on viral entry
into the brain, mice were intranasally infected and allowed to
establish HSV-1 infection for 3 days prior to receiving SFN
treatments. SFN-treated mice received i.p. injections of 50 mg/kg
SFN for 4 consecutive days (3–6 d p.i.) while control mice received
equal volumes of i.p. saline. RT-PCR detection of HSV
glycoprotein D (GlyD) expression, a viral protein indicative of
active viral replication, showed equal amounts of virus in SFN and
control treated mice, demonstrating that systemic SFN did not
impact viral entry into the brains of HSV-infected mice (Figure 6).
Flow cytometry using CD11b and CD45 antibodies found that
systemic SFN resulted in a ,50% reduction in CD11b
+, CD45
hi
macrophage/neutrophil infiltration (11.4%) compared to saline-
treated HSV-1 infected mice (22.8%) (Figure 7A). The primary
mode for macrophages to clear a pathogen is through ROS
production [24], therefore we quantified intracellular ROS in
CD11b
+, CD45
hi cells using DCFH-DA (Figure 7B). We found
Figure 3. HSV-stimulated murine microglia induce antioxidant gene expression in purified mouse astrocytes cultures. Purified
murine microglia obtained from neonatal Balb/c mice were infected with HSV-1 at 2 MOI for 90 min (+HSV2Mg) and added at a 1 to 5 microglia:
neural cell ratio to either (A) murine mixed neural cultures (consisting of neurons, astrocytes and microglia; MNC) or (B) purified murine astrocyte
cultures. Cultures were maintained for 8, 24 or 48 h before cell collection and RNA extraction. Unstimulated microglia (+Mg) and MNC or astrocyte
only cultures (C) were used as controls. Data are presented as the mean fold induction 6 standard error of the mean over saline controls (n=3).
Statistical significance was tested using an ANOVA single factor with PLSD Post-hoc analysis (StatView 5).
doi:10.1371/journal.pone.0036216.g003
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+, CD45
hi infiltrate,
a smaller percentage of infiltrating macrophage/neutrophils in
SFN treated HSV-1 mice (59%) were producing high levels of
intracellular ROS compared to saline controls (73%).
Microglia are the primary responders during viral brain
infection, producing robust amounts of cytokines and chemokines
to recruit peripheral immune cells and combat infection. Using
flow cytometric staining for MHCII, a surface protein expressed
on activated, CD11b
+, CD45
int microglia, we investigated whether
SFN treatment affected the functional state of microglial cells in
the brain during HSV-1 infection (Figure 7C). As expected, viral
infection increased the percentage of activated microglia (33%
MCHII+) [16]. In contrast, in SFN-treated HSV-1 mice 21% of
microglia had MHCII upregulated. Injection of SFN into control
mice had no effect on microglial MHCII expression.
Discussion
Herpes virus brain infection results in devastating encephalitis.
While drug therapies that inhibit viral replication have succeeded
in reducing mortality, fewer than 20% of patients surviving herpes
encephalitis recover without significant long-term neuropatholog-
ical manifestations [1,20]. The host’s innate immune system is
pivotal in mounting the initial, robust immune response during
viral brain infection and includes the activation of resident
microglia as well as the recruitment of peripheral macrophages
and neutrophils. It is becoming increasingly clear that these cells
are also liable for damage to crucial bystander tissue that is
secondary to the primary infection. Indeed, ROS production by
microglial cells is at least partially responsible for the neurotoxicity
documented during and subsequent to herpes encephalitis [3,4].
In this paper we show that boosting the antioxidant capacity of
brain cells, using SFN, can protect cultured neurons from
cytotoxic ROS-producing microglia, as well as reduce in vivo
ROS and inflammation in the brains of herpes encephalitic mice.
In vivo quantification of ROS generation is inherently difficult
due the transient nature of free radical kinetics, thus, prior to the
current study, measure of oxidative stress in the brain was based
on the accumulation of free radical-mediated tissue damage during
HSV-1 infection [3]. In this paper, we combined the sensitivity of
the ROS indicator, DCFH-DA, with the isolation of brain
leukocytes to successfully quantify intracellular free radical
production in specific immune cell populations during viral
infection. As previously reported [5], we confirm that HSV
infection resulted in a robust increase in brain CD11b
+, CD45
hi
leukocytes at 7 d p.i.. We extended these observations to show that
brain macrophages/neutrophils in herpes encephalitic mice
significantly increased their production of ROS compared to
controls (Figure 1). These data indicate that viral brain infection
results in a ROS-rich brain, a potentially toxic environment for
crucial neuronal cells. Furthermore, we report that elevated ROS
is due to both the increased number of infiltrating, ROS-
producing leukocytes as well as the upregulation of intracellular
ROS production at the level of the individual cell.
The antioxidative stress response is crucial in preventing
damage to bystander cells during ROS-mediated pathogen
clearance. Our previous studies showed that increased lumines-
cence in the brain of HO-1 promoter-luciferase expressing
transgenic mice during HSV-1 infection was indicative of a
counteractive antioxidative stress response being initiated [5].
Semi-quantitiative RT-PCR analysis of HO-1 performed in this
study confirms these previous findings and provides evidence of a
more extensive antioxidative response, including the recruitment
of Gpx1 (Figure 2). Interestingly, Nrf2 mRNA expression did not
increase in infected mice despite an increase in its downstream
transcriptional targets, HO-1 and Gpx1. Activation of Nrf2 is
dependent on its dissociation from the cytosol sequestering/
degradation-targeting Kelch-like ECH-associating protein 1
(Keap1) [25]. It is likely that, at rest, sufficient cellular Nrf2
protein is available in the cytosol and that the Nrf2/ARE
antioxidant pathway is triggered not by increased expression of
Nrf2, but by the translocation of existing Nrf2 into the nucleus.
Nonetheless, although present, the antioxidant response in the
brains of encephalitic mice is insufficient to perturb the high
mortality and accumulation of oxidative damage that is charac-
teristic of HSV-1 brain infection [15,16].
Oxidative stress insults have been shown to trigger antioxidant
responses in neurons, astrocytes and microglial cells [26,27,28].
Neurons, while capable of implementing an antioxidant response,
are still highly susceptible to ROS because of a relatively low level
of resting glutathione and poor upregulation of antioxidant
enzymes [29,30]. We found that MNCs, consisting largely of
neurons (85–90% neurons, 10–15% astrocytes, ,2% microglia),
fail to upregulate key antioxidants, HO-1 and Gpx1, upon
exposure to HSV-stimulated microglia (Figure 3). Similarly, HSV-
stimulated microglia reduced GSH levels in MNCs (Figure 4).
MNCs also contain astrocytes, which are thought to be the
primary source of antioxidant production in the brain [21,22]. In
support of this notion, we found that purified murine astrocytes
respond to HSV-stimulated microglia by increasing expression of
HO-1, Gpx-1 and Nrf2 mRNA (Figure 3), indicating that the lack
of detectable astrocyte-associated HO-1 and Gpx1 upregulation in
MNCs was not due to the astrocyte’s inability to produce the
antioxidants but rather their low overall number in the MNC
system. Based on the delayed upregulation of astrocyte antiox-
idants ($48 h), the low percentage of astrocytes in MNC (10–
15%) and the rapid production of ROS in HSV-1 (,3 hpi)
Figure 4. Reduced GSH production in MNCs exposed to HSV-
stimulated microglia. Purified murine microglia obtained from
neonatal Balb/c mice were infected with HSV-1 at 2 MOI for 90 min
(+HSV2Mg) and added at a 1 to 5 microglia: neural cell ratio to MNC.
Cultures were maintained for 48 h before quantification of GSH
concentration (mM). Unstimulated microglia (+Mg) and MNC only
cultures were used as controls. Statistical significance was tested using
an ANOVA single factor with PLSD Post-hoc analysis (StatView 5).
*p#0.0001.
doi:10.1371/journal.pone.0036216.g004
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36216Figure 5. Sulforaphane elevates HO-1 expression via Nrf2/ARE activation in astrocytes. SFN (0, 0.3, 1.0 or 3.0 mM) was added onto MNC
for 8 & 24 h prior to collection for semi-quantitative RT-PCR (A&B ) and Western blot (C) analysis. RT-PCR of HO-1 (A) and GCLM (B) mRNA
expression in MNCs following 8 & 24 h exposure to SFN. Data are presented as fold induction over saline controls and are representative of 3 separate
experiments. (C) Western blot analysis of HO-1 protein expression in MNCs following 8 & 24 h exposure to SFN. (D) GSH concentration in MNCs
following 48 h exposure to SFN (p#0.0001). (E) SFN treated MNC (24 h) stained for HO-1 (green) and GFAP (red). Scale=50 mm. (F) ARE-Luciferase
reporter assay in purified astrocyte cultures following 4 and 8 h SFN treatment. *p=0.007; **p=0.006. Statistical significance was tested using an
ANOVA single factor with PLSD Post-hoc analysis (StatView 5).
doi:10.1371/journal.pone.0036216.g005
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MNC is insufficient to combat the robust free radical production
and subsequent neurotoxicity mediated by virus-exposed microg-
lia.
Antioxidant enhancement is a promising therapeutic strategy
for modulating brain inflammation and associated neurotoxicity
[31,32]. Sulforaphane enhances cellular antioxidant levels by
activation of the Nrf2/ARE pathway, resulting in the upregulation
of phase II antioxidant enzymes HO-1 and Gpx1 [12], both of
which have been found to have neuroprotective actions during
brain inflammation [32] [13,20]. SFN has been found to confer
neuroprotection in animal models of Parkinson’s Disease,
ischemia, traumatic brain injury and glutamate excitotoxicity
[7,13,33,34,35] suggesting its potential use as a treatment for
oxidative stress during HSV-encephalitis. In this study, we
demonstrate that SFN promotes an antioxidant response in
MNC (Figure 5). This response appears to derive primarily from
the astrocytes within the MNC (Figure 5E) and occurs via
activation of the Nrf2/ARE complex (Figure 5F). Indeed, Nrf2-
mediated antioxidant upregulation in astrocytes is thought to be
the primary neuroprotective mechanism in the brain against ROS-
induced neurotoxicity [36,37]. Most important was our observa-
tion that SFN pretreatment conferred significant protection to
neurons in MNCs from exposure to HSV-stimulated microglia
(Figure 6). These data implicate SFN as a candidate therapeutic
for viral infection-induced brain neurotoxicity. Although, HO-1,
Gpx1 and GSH were used in this study as indicators of SFN action
in the brain, these studies are not meant to imply that SFN’s
neuroprotective effects are fully mediated by a single antioxidant.
Indeed, studies have shown that overexpression of single
antioxidants provides insufficient neuroprotection in comparison
to compounds that simultaneously upregulate multiple antioxi-
dants [38].
Based on our in vitro data, the ability of SFN to cross the blood-
brain barrier [12], and evidence that systemic SFN increases brain
antioxidant gene expression, decreases microglial activation, and
blunts neutrophil infiltration [12,39], we investigated the effect of
systemic SFN on the inflammatory response triggered during
herpes encephalitis. We found that SFN treatment significantly
decreased ROS production in CD11b
+, CD45
hi macrophage/
neutrophils when compared to untreated HSV-infected mice
(Figure 8B). In addition to reduced leukocyte-produced ROS, a
more profound anti-inflammatory profile was observed in the
brain of SFN-treated encephalitic mice. We found that SFN
treatments significantly decreased microglial cell activation
Figure 6. Sulforaphane protects mixed neural cultures from
HSV-stimulated microglial neurotoxicity. Mixed neural cultures
from b-actin luciferase Balb/c mice were pretreated for 24 h with SFN
(0, 0.3, 1.0 and 3.0 mM). Purified murine microglia from Balb/c mice
(non-luciferase expressing) were infected with HSV-1 at 2 MOI for
90 min (+HSV2Mg) and added at a 1 to 5 microglia: neural cell ratio.
Cultures were maintained for 48 h before analysis of neurotoxicity via
(A) luminescence or (B) immunohistochemistry. Unstimulated microglia
(+Mg) and MNC or astrocyte only cultures (C) were used as controls. (A)
Data are presented as mean luciferin intensity (% of MNC only control)
6 SD. These data are representative of 3 separate experiments. *p#0.1;
**p#0.05. (B) MAP-2 immunohistochemistry (green) in MNCs alone
(Control), MNCs with unstimulated microglia (MG), and MNCs with HSV-
stimulated microglia alone (HSV2MG) or following 3 mm SFN treatment
(HSV2MG+HSV). Cells counterstained with propidium iodide (red).
Scale=50 mm.
doi:10.1371/journal.pone.0036216.g006
Figure 7. Sulforaphane does not affect establishment of HSV
brain infection. Balb/c mice were infected with HSV-1 and given four
100 ml doses of SFN (50 mg/kg) or saline between 3–6 d p.i.. At 7 d p.i.
subcortical tissue was collected, mRNA extracted and cDNA synthesized
for semi-quantitative RT-PCR of HSV-1 glycoprotein D expression.
doi:10.1371/journal.pone.0036216.g007
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macrophages/neutrophils (Figure 8A). Microglial cells, which
normally do not express MHCII but upregulate the activation
marker by exposure to interferon-c [40], were shown to express
significantly less MHCII in HSV-infected mice treated with SFN.
Taken together with our observation that SFN reduced macro-
phage/neutrophil-produced ROS, these data indicate a less
inflamed and less ROS rich brain environment upon systemic
infusion of SFN, supporting its therapeutic potential during viral
encephalitis.
Despite reports in the literature [13,41], our regiment of
systemic SFN treatment did not markedly increase brain HO-1
expression in control, uninfected mice. Repeated administration of
SFN in vivo is likely to attenuate HO-1 production, a phenomenon
reported in cultured astrocytes [42], as a negative feedback
mechanism to prevent excess antioxidant expression. The effects of
SFN in the brain may be kept quiescent until presentation of an
oxidative stress insult (i.e., viral brain infection), during which its
anti-inflammatory actions are required. In our model, intranasal
HSV infection alone induced robust HO-1 expression in the brain
(Figure 2), such that a significant difference in HO-1 expression in
HSV-infected, SFN-treated mice was not detectable. Future
experiment are needed to examine the kinetics of SFN action in
the brain and determine whether its beneficial actions are due to
its ability to mount a quicker or more prolonged antioxidant
response, rather than a simple correlation with the level of
antioxidant expression in the brain,
Figure 8. Systemic sulforaphane reduces macrophage infiltration, macrophage-specific ROS, and microglial activation in the brains
of herpes encephalitic mice. Balb/c mice were infected with HSV-1 and given four 100 ml doses of SFN (50 mg/kg) or saline between 3–6 d p.i.. At
7 d p.i. whole brain leukocytes were isolated and stained for flow cytometry. (A) Flow cytometry plots of CD45 and CD11b staining in both
uninfected and HSV-infected mice with or without SFN treatment. CD11b
+, CD45
hi macrophages and neutrophils are highlighted in the upper box
and microglial cells (CD11b
+, CD45
int) in the lower box. (B) CD11b
+, CD45
hi macrophages/neutrophils were gated on for DCFH-DA analysis of ROS
production. Cells were subdivided into high (bottom right quadrant) and low (bottom left quadrant) DCFH-DA expressing groups. (C) The percentage
of activated microglial cells activation was assessed in both uninfected and HSV-infected mice with or without SFN treatment by detection of MHCII
expression on CD11b
+, CD45
int cells.
doi:10.1371/journal.pone.0036216.g008
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HSV-infected brain does not appear to be a result of SFN affecting
viral entry into the brain because a similar amount of viral
expression was observed in control untreated encephalitic mice
(Figure 7). Rather, it is likely a secondary effect of the SFN-
mediated reduction in macrophage ROS production. Our
previous work showed that ROS production drives synthesis of
cytokines and chemokines in HSV-stimulated murine microglia
[4]. Similarly, inhibition of NADPH oxidase, the primary cellular
manufacturer of the superoxide free radical, has been shown to
reduce the production of cytokine/chemokines in macrophages
and decrease macrophage-mediated neurotoxicity in response to
HIV-tat stimulation [43]. Thus, reduced ROS production in
macrophages initially recruited into the brain during HSV-1
infection may result in their blunted production of cytokines and
chemokines. Reduced levels of essential proinflammatory media-
tors such as interferon-c and macrophage chemoattractant
protein-1, would subsequently blunt the continued recruitment
of peripheral macrophages as well as the activation of resident
microglial cells [14,44].
Due to the aggressive replication and lytic nature of HSV-1
infection, it is unlikely that prophylactic SFN would protect against
fatal herpes encephalitis in the absence of antiviral therapy.
Indeed, we found equal mortality outcomes in both saline and
SFN-treated HSV-infected mice. However, post-encephalitic mice
continue to have active and persistent brain inflammation which is
associated with manifestation of severe cognitive deficits [15]. Data
presented in this manuscript support the notion that patients may
benefit from SFN treatments used in combination with antiviral
therapy during active herpes encephalitis, as well as when given
during post-encephalitic recovery.
Materials and Methods
Ethical Statement
The animal use protocols used were approved by the University
of Minnesota Institutional Animal Care and Use Committee
(Protocol Number: 1105A99494).
Virus
HSV-1 strain 17 syn+ was propagated and titrated using a
plaque assay on rabbit skin fibroblasts (CCL68; American Type
Culture Collection, Manassas, VA).
Intranasal HSV-1 infection
Eight to ten-week-old female Balb/c mice (Charles River
Laboratories
TM, Boston, MA, USA) were infected via intranasal
administration with 1.0610
5 HSV-1 plaque-forming units (PFU)/
nostril (2.0610
5 PFU/mouse). At 7 d p.i., mice were anaesthe-
tized with ketamine/xylazine, decapitated and brains dissected for
flow cytometric analysis or RNA extraction.
Sulforaphane treatments
R,S-Sulforaphane was purchased form LKT Laboratories (St.
Paul, MN) and added to mixed neural cultures or purified
astrocyte cultures at 0, 0.3, 1.0, 3.0 mM. Systemic sulforaphane
was administered at 50 mg/kg.
Isolation of brain leukocytes and flow cytometry
Leukocytes were isolated from HSV-infected murine brains
using a previously described procedure [45,46]. Briefly, brain
tissues harvested from 4 to 6 animals were minced finely in RPMI
(2 g/L d-glucose and 10 mM HEPES) and mechanically disrupted
(in Ca/Mg free HBSS) at room temperature for 20 min. Single
cell preparations from infected brains were resuspended in 30%
Percoll and banded on a 70% Percoll cushion at 900 g at 15uC.
Brain leukocytes obtained from the 30% to 70% Percoll interface
were stained with anti-mouse immune cell surface markers for
45 min at 4uC (CD45-Allophycocyanin (APC), CD11b-APC-CY7,
MHC Class II-phycoerythrin (PE); BD Biosciences, San Jose, CA)
and analyzed by flow cytometry using a BD FACSCanto. Live
leukocytes were gated using forward scatter and side scatter
parameters and analyzed using FlowJo software (TreeStar, Inc.).
The production of intracellular ROS was measured by the
oxidation of 29,79-Dichlorofluorescin diacetate (DCFH-DA; Sig-
ma; St. Louis, MO).
Real Time PCR
Real-time PCR was performed on both cultured cells and fresh
tissue. Cell culture extracts were collected and RNA purified using
a RNAse Easy Kit (Qiagen). RNA was extracted from murine
brains using a 2-mm-thick section of subcortical (bregma
,4.0 mm). The fragment was trimmed of excess cortical tissue
and the remaining subcortex assessed for mRNA expression of
anti-oxidative enzyme mRNA. Total RNA was extracted from
brain tissue homogenates using the TRIzol Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions. For
both in vitro and in vivo collected RNA, cDNA was synthesized
using 1 to 5 mg of total RNA, SuperScript II reverse transcriptase
(Invitrogen Life Technologies, Carlsbad, CA) and oligo dT6–12
primers (Sigma-Genosys, The Woodlands, TX). Semi-quantitative
real-time PCR was performed using the FullVelocity SYBR Green
QPCR master mix (Stratagene, La Jolla, CA). The 25 ml final
reaction volume consisted of premade reaction mix (SYBR Green
I dye, reaction buffer, Taq DNA polymerase, and dNTPs),
0.3 mM of each primer, and 0.5 ng cDNA in water. Reaction
conditions for PCR for the Mx3000P QPCR System (Stratagene)
were as follows: polymerase activation at 95uC for 5 min, 40
denaturation cycles of 95uC for 10 s, and annealing/elongation at
60uC for 30 s. The relative product levels were quantified using
the 2(-Delta Delta C(T)) method [47] and were normalized to the
housekeeping gene hypoxanthine phosphoribosyl transferase-
encoding (HPRT; NM_013556). Forward and reverse primer
sequences were designed from the murine genes of: heme
oxygenase-1 (HO-1; NM_010442): 59-cacgcatatacccgctacct-39
and 59-ccagagtgttcattcgagca-39; glutathione peroxidase-1 (Gpx1;
NM_008160): 59-gtccaccgtgtatgccttct-39 and 59-cctcagagagacgcga-
catt-39; nuclear factor-E2-related factor 2 (Nrf2; NM_010902): 59-
atgccagccagctgacctcctta-39 and 59-agacggtggcagcatgccttc-39; glu-
tatmate cysteine ligase modifier (GCLM; NM_008129.3): 59-
ccttggagcatttacagccttact-39 and 59- agttctttcgggtcattgtgagtc-39;
HSV Glycoprotein D (GlyD): 59-atccgaacgcagccccgctg-39 and
59-tctccgtccagtcgtttatctt-39.
Glutathione measurements
Total glutathione concentration was determined using the
GSH-Glo(TM) Glutathione Assay Kit (Promega; Madison, WI).
Microglial cell cultures
Murine cerebral cortical cells from 1-day-old Balb/c mice were
dissociated after a 30- min trypsinization (0.25%) and were plated
in 75-cm
2 Falcon culture flasks in DMEM containing 10% heat-
inactivated fetal bovine serum (FBS) and antibiotics. The medium
was replenished 1 and 4 days after plating. On day 12 of culture
harvested cells were plated in a 60-mm petri dish and incubated
for 15 min at 37uC. After extensive washing with culture medium,
adherent microglia were collected with a rubber policeman and
centrifuged at 1000 rpm for 10 min. Purified microglial cell
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stained positively with MAC-1 antibodies and ,2% stained
positively with antibodies specific to glial fibrillary acid protein, an
astrocyte marker. For qPCR and neurotoxicity assays, purified
murine microglia were stimulated with HSV-1 (2 MOI) for 90 min
in suspension. To eliminate residual HSV-1 particles, microglia
were lightly trypsinized (0.1% trypsin in hank’s balanced salt
solution) for 15 minutes, rinsed two times in serum free DMEM
and resuspended in 7% FBS DMEM. Microglia were then added
to mixed neural cultures or astrocytes at a 1:5 microglial to neural
cell ratio.
Neural cell cultures
Separate neural cell cultures were established from wild-type
Balb/c and transgenic b-actin promoter-luciferase Balb/c mice.
Following dispersion of fetal (d 15 of gestation) cerebral cortices
with trypsin, cells (5610
5 or 2610
5/500 ml) were plated into
collagen coated wells of 24-well plates with DMEM containing
10% heat-inactivated FBS and antibiotics. On day 5, the culture
medium was replaced with DMEM containing 10% heat-
inactivated FBS, uridine (33.6 mg/ml), and fluorodeoxyuridine
(13.6 mg/ml) to suppress glial cell growth. After 24 h, cells were
replaced with DMEM containing 10% heat-inactivated FBS.
Culture medium was changed every 4 days thereafter. On day 7
the neural cell cultures consisted of approximately 85–90%
neurons (stained with a rabbit anti-MAP-2 antibody (Millipore;
#AB5622; 5 mg/mL) and containing characteristic processes and
birefringent cell bodies), 10–15% astrocytes (stained with rabbit
anti-glial fibrillary acid protein antibody; Incstar, Stillwater, MN),
and ,2% microglia (stained with a rat anti-MAC-1 antibody;
Roche Applied Science, Indianapolis, IN).
Astrocyte cultures
Astrocytes were prepared from 1- to 2-day-old neonatal Balb/c
mice. Brain tissues were dissociated and resuspended in DMEM
containing penicillin (100 U/ml), streptomycin (100 mg/ml),
gentamicin (50 mg/ml) and FungizoneH (250 pg/ml) and plated
onto poly-L-lysine (20 mg/ml)-coated 75-cm
2 flasks at a density of
80–100610
6 cells/flask and incubated at 37uC in a 6% CO2
incubator. Culture medium was changed at a weekly interval. On
day 21, flasks were shaken at 180–200 rpm for 16 h followed by
trypsinization with 0.25% trypsin in HBSS for 30 min. After
adding FBS (final concentration 10%), centrifugation and washing,
cells were seeded into new flasks with DMEM followed by medium
change after 24 h. The subculture procedure was repeated four
times at a weekly interval to achieve highly purified astrocyte
cultures (99% of cells reacted with GFAP antibody) which were
plated onto 24-well tissue culture plate (0.5 to 1610
6 cells/well)
plates for RNA extraction.
Immunocytochemistry
Mixed neural cultures plated onto chamber slides were fixed
with 4% paraformaldehyde followed by washing with PBS and
incubation with 10% normal donkey serum in PBS for 1 h at
room temperature (RT). Primary antibodies for mouse anti-HO-1
(Assay Design; #OSA-110; 1:100), rabbit anti-GFAP antibodies
(1:1000, 1 mg/ml), mouse anti-MAP-2 (Millipore; #AB5622;
5 mg/mL), or anti-NeuN antibody (Chemicon, Temecula, CA;
1:100) were added and incubated overnight at 4uC. After washing,
secondary antibody (rhodamine- or FITC-conjugate) was added
for 1 h at RT followed by nuclear labeling with Hoechst 33342
(Chemicon, Temecula, CA; 1 mg/ml) and viewing under fluores-
cent microscope.
Neurotoxicity assay
Purified murine microglia from wild-type Balb/c mice were
stimulated with HSV-1 (2 MOI) for 90 min in suspension. To
eliminate residual HSV-1 particles, microglia were lightly
trypsinized (0.1% trypsin in hank’s balanced salt solution) for
15 minutes, rinsed two times in serum free DMEM and
resuspended in 7% FBS DMEM. Microglia were then transferred
at a 1:5 microglia to neuron ratio onto cultured neurons obtained
from b-actin promoter-luciferase transgenic mice. D-Luciferin
potassium salt (Gold Biotechnology; St. Louis, MO) was added to
each well and luciferase activity measured on a plate reader 48 h
after microglial cell transfer. MNCs were pretreated for 24 h with
select concentrations (0, 0.3, 1.0, 3.0 mm) of SFN prior to transfer
of microglia.
Western Blot
Following SFN treatment cell lysates were collected, electro-
phorezed in 12% acrylamide/bis-acrylamide electrotransfered
onto nitrocellulose membrane and probed with mouse anti-HO-
1 antibody (Assay Design; #OSA-110). A rabbit anti-b-actin
antibody (Cell Signaling; #4970) was used as a loading control.
Alkaline phosphatase-conjugated secondary antibodies with
chemiluminescence detection was used with a Kodak Image
Station to capture protein band images.
Statistical analysis
For comparison of means of multiple groups, analysis of
variance (ANOVA) was performed followed by a Fisher’s
protected least significant difference (PLSD)-test. For comparison
of means of pairs of data a two-tailed Student’s T-test for paired
samples was applied.
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